巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-12-30
2021-10-19
2023-03-04
2022-01-08
2023-02-22
2021-11-26
2021-05-05
2021-11-10
2021-12-23
2021-11-27
2023-06-07
2021-10-25
